Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis
Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman
Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman
View: Text | PDF
Research Article Metabolism

HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis

  • Text
  • PDF
Abstract

Carbohydrate response element–binding protein (ChREBP) is a carbohydrate-sensing transcription factor that regulates both adaptive and maladaptive genomic responses in coordination of systemic fuel homeostasis. Genetic variants in the ChREBP locus associate with diverse metabolic traits in humans, including circulating lipids. To identify novel ChREBP-regulated hepatokines that contribute to its systemic metabolic effects, we integrated ChREBP ChIP-Seq analysis in mouse liver with human genetic and genomic data for lipid traits and identified hepatocyte growth factor activator (HGFAC) as a promising ChREBP-regulated candidate in mice and humans. HGFAC is a protease that activates the pleiotropic hormone hepatocyte growth factor. We demonstrate that HGFAC-KO mice had phenotypes concordant with putative loss-of-function variants in human HGFAC. Moreover, in gain- and loss-of-function genetic mouse models, we demonstrate that HGFAC enhanced lipid and glucose homeostasis, which may be mediated in part through actions to activate hepatic PPARγ activity. Together, our studies show that ChREBP mediated an adaptive response to overnutrition via activation of HGFAC in the liver to preserve glucose and lipid homeostasis.

Authors

Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman

×

Figure 2

ChREBP links nutritional status to circulating HGFAC.

Options: View larger image (or click on image) Download as PowerPoint
ChREBP links nutritional status to circulating HGFAC.
(A) ChIP was perfo...
(A) ChIP was performed from livers of control and ChREBP-LKO mice with anti-ChREBP or control IgG. qPCR was performed on immunoprecipitated chromatin with primers spanning the E-box in the Pklr promoter and the putative ChREBP binding site in proximity to HGFAC and in nonspecific regions (neg) in proximity to both ChREBP response elements (n = 3/group). (B) Hepatic Chrebpβ and Hgfac mRNA expression of overnight-fasted and 4-hour chow- or HFrD-fed Wistar rats (n = 7/group). (C) Liver mRNA expression and (D) circulating levels of HGFAC in control and ChREBP-LKO mice after 8 weeks on chow versus HFrD with densitometric quantification (n = 4–5/group). (E) Correlation between HGFAC mRNA expression and a composite vector comprising canonical ChREBP targets in human livers from the GTEx project (Pearson’s correlation R2 = 0.44, P < 0.0001, n = 226). (F) Factors ranked by odds ratio for enrichment of the 300 genes most highly coexpressed with the factor in the ARCHS4 project that are also present in the top 5% of genes that correlate with HGFAC expression in the GTEx project. Combined score = log(P) × z, where P is calculated by Fisher’s exact test and z score is calculated by assessing the deviation from the expected rank. The size and color of the circles correspond to the enrichment score and adjusted P value, respectively. (G) Expression of HGFAC mRNA in livers of healthy controls, obese nondiabetic participants, and obese participantswith well-controlled diabetes and poorly controlled diabetes, (n = 4–5/group). Data represent means ± SEM. Statistics were assessed by 2-way ANOVA with Holm-Šídák multiple comparisons between individual groups, #P < 0.05, for main effects, ^P < 0.05 for comparison across genotypes within diets; or 1-way ANOVA with Holm-Šídák multiple comparisons test between control and other groups, &P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts